Koo Wilson

707 total citations
44 papers, 547 citations indexed

About

Koo Wilson is a scholar working on Hematology, Immunology and Genetics. According to data from OpenAlex, Koo Wilson has authored 44 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hematology, 14 papers in Immunology and 10 papers in Genetics. Recurrent topics in Koo Wilson's work include Complement system in diseases (13 papers), Blood groups and transfusion (13 papers) and Platelet Disorders and Treatments (9 papers). Koo Wilson is often cited by papers focused on Complement system in diseases (13 papers), Blood groups and transfusion (13 papers) and Platelet Disorders and Treatments (9 papers). Koo Wilson collaborates with scholars based in Sweden, United Kingdom and United States. Koo Wilson's co-authors include Lalit Kalra, F Harraf, Kristian Bolin, Ann‐Christin Mörk, David Gillen, Jameel Nazir, Henri‐Jean Aubin, Enrico De Nigris, Jesse Fishman and Jelena Jovanović and has published in prestigious journals such as Blood, Heart and Clinical Journal of Pain.

In The Last Decade

Koo Wilson

42 papers receiving 533 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Koo Wilson Sweden	14	154	153	102	75	74	44	547
Sue Gao United States	13	194 1.3×	99 0.6×	100 1.0×	114 1.5×	30 0.4×	20	867
Birkan İlhan Türkiye	15	235 1.5×	87 0.6×	34 0.3×	83 1.1×	49 0.7×	45	707
Greg Carney Canada	12	39 0.3×	53 0.3×	55 0.5×	44 0.6×	45 0.6×	37	620
Fries Jf United States	12	49 0.3×	45 0.3×	152 1.5×	44 0.6×	82 1.1×	27	747
Robert Offer Canada	6	30 0.2×	211 1.4×	56 0.5×	32 0.4×	60 0.8×	6	582
Karen Murphy Ireland	11	64 0.4×	53 0.3×	42 0.4×	86 1.1×	73 1.0×	24	695
Sabine Gaugris United States	13	288 1.9×	162 1.1×	40 0.4×	45 0.6×	90 1.2×	20	903
Víctor Gil Portugal	14	59 0.4×	52 0.3×	41 0.4×	371 4.9×	114 1.5×	81	690
Gamal Saadi Egypt	11	40 0.3×	49 0.3×	31 0.3×	41 0.5×	55 0.7×	72	501
Yoshitaka Ishibashi Japan	14	114 0.7×	23 0.2×	45 0.4×	36 0.5×	146 2.0×	54	688

Countries citing papers authored by Koo Wilson

Since Specialization

Citations

This map shows the geographic impact of Koo Wilson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koo Wilson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koo Wilson more than expected).

Fields of papers citing papers by Koo Wilson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koo Wilson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koo Wilson. The network helps show where Koo Wilson may publish in the future.

Co-authorship network of co-authors of Koo Wilson

This figure shows the co-authorship network connecting the top 25 collaborators of Koo Wilson. A scholar is included among the top collaborators of Koo Wilson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koo Wilson. Koo Wilson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Latour, Régis Peffault de, Austin Kulasekararaj, David Dingli, et al.. (2025). Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria. European Journal Of Haematology. 115(2). 125–133.

Cooper, Nichola, Sı́lvia Stanisçuaski Guterres, Koo Wilson, et al.. (2025). The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK. Journal of Market Access & Health Policy. 13(2). 11–11. 1 indexed citations

Wilson, Koo, Francesca Chiodi, Zalmaï Hakimi, et al.. (2025). Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL After ≥ 2 Lines of Therapy: Matching-Adjusted Indirect Comparison. Advances in Therapy. 42(5). 2445–2464. 1 indexed citations

Wilson, Koo, Francesca Chiodi, Zalmaï Hakimi, et al.. (2024). CO143 Loncastuximab Tesirine Versus Glofitamab for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy: A Matching-Adjusted Indirect Comparison. Value in Health. 27(12). S41–S41. 1 indexed citations

Panse, Jens, Koo Wilson, Jesse Fishman, et al.. (2023). Fatigue and health‐related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data. European Journal Of Haematology. 111(1). 72–83. 4 indexed citations

Wong, Raymond, Jesse Fishman, Koo Wilson, et al.. (2023). Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison. Advances in Therapy. 40(4). 1571–1589. 5 indexed citations

Wilson, Koo, Carly Rich, Zalmaï Hakimi, et al.. (2023). Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health‐related quality of life and productivity. European Journal Of Haematology. 112(4). 516–529. 5 indexed citations

Rich, Carly, Koo Wilson, Jens Olsen, Mikkel W. Pedersen, & Henrik Frederiksen. (2023). The disease burden of paroxysmal nocturnal hemoglobinuria in Denmark: Epidemiology, survival, healthcare resource utilization, costs, treatment gaps, and labor market attachment. European Journal Of Haematology. 112(3). 412–423. 1 indexed citations

Wojciechowski, Piotr, et al.. (2021). PDB34 Comparative Efficacy and Safety of Avatrombopag Versus Lusutrombopag in Patients with Chronic LIVER Disease and Severe Thrombocytopenia Undergoing Invasive Procedures: A Systematic Literature Review and Network Meta-Analysis. Value in Health. 24. S84–S84. 2 indexed citations

10.

Wojciechowski, Piotr, et al.. (2021). Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis. Advances in Therapy. 38(6). 3113–3128. 13 indexed citations

11.

Bullement, Ash, et al.. (2019). Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data. PharmacoEconomics - Open. 4(1). 133–142. 12 indexed citations

12.

Bullement, Ash, et al.. (2019). RO4 COST-EFFECTIVENESS ANALYSIS OF RFVIIIFC, PEGYLATED RFVIII, AND EMICIZUMAB FOR THE PROPHYLACTIC TREATMENT OF SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN THE UNITED STATES. Value in Health. 22. S389–S389. 2 indexed citations

13.

Pérez, Concepción, et al.. (2014). Modeling the Predictive Value of Pain Intensity on Costs and Resources Utilization in Patients With Peripheral Neuropathic Pain. Clinical Journal of Pain. 31(3). 273–279. 20 indexed citations

14.

Bolin, Kristian, et al.. (2011). Current and future avoidable cost of smoking – Estimates for Sweden 2007. Health Policy. 103(1). 83–91. 13 indexed citations

15.

Wilson, Koo, et al.. (2011). A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy. 12(17). 2613–2626. 17 indexed citations

16.

Bolin, Kristian, et al.. (2009). Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation—results from four European countries. European Journal of Public Health. 19(6). 650–654. 40 indexed citations

17.

Wilson, Koo, et al.. (2008). Análisis coste-efectividad de vareniclina (Champix®) en el tratamiento del tabaquismo en España. Anales de Medicina Interna. 25(7). 342–8. 20 indexed citations

18.

Wilson, Koo, et al.. (2003). The Economic Burden of Stroke in the United Kingdom. PharmacoEconomics. 21(Supplement 1). 43–50. 124 indexed citations

19.

Wilson, Koo, John Marriott, Stephen J. Fuller, Loretto Lacey, & David Gillen. (2003). A Model to Assess the Cost Effectiveness of Statins in Achieving the UK National Service Framework Target Cholesterol Levels. PharmacoEconomics. 21(Supplement 1). 1–11. 16 indexed citations

20.

Buller, Nigel, David Gillen, Roman Casciano, John C. Doyle, & Koo Wilson. (2003). A Pharmacoeconomic Evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study in the United Kingdom. PharmacoEconomics. 21(Supplement 1). 25–32. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact